Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimenAdolfo de Salazar, Eiko Schnaitmann, Julia Dietz et al.|Journal of Antimicrobial Chemotherapy|2020Cited by 22
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 InfectionsJulia Dietz, F. Kocheise, Felix Piecha et al.|Clinical Gastroenterology and Hepatology|2019Cited by 13
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patientsJulia Dietz, R. Zachoval, Christiana Graf et al.|JHEP Reports|2024Cited by 8
934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITYJohannes Vermehren, C. Sarrazin, Alessio Aghemo et al.|Journal of Hepatology|2012Cited by 2
Real World Experience of Prescribing Tenofovir Alafenamide for Chronic Hepatitis B Patients in GermanyJ. Petersen, Peter Buggisch, Christian Hoffmann et al.|Zeitschrift für Gastroenterologie|2019Cited by 0